Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
Yes but unfortunately approval clearly appears to have very little to do with product excellence, efficacy or speed of result.
Once again, one is drawn to wondering what influences the decision making process when you see how much money Innova has been given for a massively inaccurate and misleading test.
Hopefully time will reveal how these decisions were made. Too late for many that have died from false results but hopefully not to late for Avacta to demonstrate its excellence in the UK.
I suspect, based on how previous Government decisions based on who you know or are willing to give yourself to that AS neither went to school/university with the right people, nor was he willing to drop his trousers. Maybe third world countries won't be so choosy and have greater wisdom than our shambolic crown.
Already we are over 800 postings today and still 7 hours of today left. Such an incredible waste of metaphoric Ink or breath which will ultimately change nothing, influence nobody but will have upset and insulted quite a lot.
jdt1990: I'm not sure what qualifies you to lecture me. As for what you say. There is nothing that I did not already know and agree with. I am not critisising the scientific aspects of the business, the products, particularly AVA and Elisa, or the team, so many PhDs.
My only critisism, which I believe has impacted on the share price, has been to prematurely build up shareholders expectations, which in the case of the LFT they have to date failed to deliver jdt1990.
jdt1990: So after all the insults, let me ask a question of you, who is so wise about Avacta.
I first invested in Avacta in April 2020 at 78p. I have studied the company's progress closely since, I do understand a lot of the science and am university educated. Subsequent to that I have bought on 11 further occasions the highest of which was in May last year at 211p and the most recent in October 2020 at £1.80. My continuing loyalty and continued investment was based upon corporate news releases, presentations, media briefings and RNSs all of which painted positive pictures of all aspects of the business.
I must confess to being a little disappointed with progress made, specifically with regard to Covid oriented products. Progress here has not, in my opinion, lived up to corporately projected predictions. Which I think may perhaps currently be described as an over egged pudding. And yes I do understand that the development of new drugs, particularly as complex as these is prone to setbacks.
According to you my current point of view is to be sneered at.
So given that your apparent knowledge and expertise greatly exceeds mine, please give me the benefit of your wisdom.
To what do you attribute the fall in price from, let's say around May of last year at £2 to £1.23 @ 11 .49am today.
jdt1990: I'm not sure what qualifies you to lecture me. As for what you say. There is nothing that I did not already know and agree with. I am not critisising the scientific aspects of the business, the products, particularly AVA and Elisa, or the team, so many PhDs.
My only critisism, which I believe has impacted on the share price, has been to prematurely build up shareholders expectations, which in the case of the LFT they have to date failed to deliver jdt1990.
Thank you for your kind words.
I imagine the reason why you missed it was because of your blindingly obvious stupidity, coupled with rudeness, ignorance and lack of civility and common decency. But hey you carry on.